Recently, the State Food and Drug Administration (CFDA) canceled online retailing of Internet third-party platform drugs and said it would strengthen supervision over prescription drug sales. The development of medical e-commerce on the pure line has been subject to a lot of policy restrictions, and can only expand the services based on offline pharmacies, including B2C and O2O. Why are platform-based medical e-commerce not supported by policy? What kind of policy support can medical e-commerce develop? Can pharmaceutical e-commerce become an independent market?
First of all, as far as the policy is concerned, in the future, pharmaceutical e-commerce and pharmaceutical retail sales will be strengthened. This time, the online retail trial of Internet third-party platform drugs was stopped. The Food and Drug Administration officially quoted the contents of the China Medical News on the official website, emphasizing that “the third-party platform and the entity pharmacy are exposed to unclear responsibility during the pilot process, and the prescription drugs and drugs are sold. Quality and safety are difficult to effectively monitor and other issues." Judging from the above cited contents, there are many problems in the medical e-commerce itself, which leads to the need for the government to reassess the feasibility of this business development. It is logical to temporarily close this business.
Like other medical industries, medical e-commerce is also a highly regulated market. To gain development, this market must be recognized by the policy and then supported. The expansion of any emerging business will encounter many irregular problems in the early days, but how to solve this irregularity and then make this market run smoothly is the key. From the current point of view, the government's supervision of offline pharmacies has been standardized, and administrative means and related tools can effectively carry out strong supervision. However, in the field of medical e-commerce, various violations are more serious, and the government does not have a set of perfect standards to regulate the market, and tools based on standards are also scarce. Therefore, whether industry regulatory standards and regulatory tools can be shaped will be an important factor in whether the policy window can be reopened.
Secondly, for medical e-commerce, the biggest policy advantage is that the prescription drug online sales will be lifted. If the hospital's outpatient pharmacy is completely removed, retail channels including medical e-commerce will benefit. However, in the absence of regulatory standards and tools, it is impossible to release the ban on prescription drugs, which will lead to further enlargement of the market's original problems, which will lead to greater challenges. As for the out-migration of hospital outpatient pharmacies, more benefits are still offline retail pharmacies, not medical e-commerce. Because, in terms of the timeliness of drug acquisition, the speed of purchase and the degree of trust, online can not be compared with offline pharmacies. Therefore, policy support is not a prerequisite for the development of pharmaceutical e-commerce, but only provides access. Even if the policy window is reopened, it will not help the market expansion of pharmaceutical e-commerce.
We're professional Medical Accessory Device manufacturers and suppliers in China, specialized in providing high quality medical instruments with reasonable price. We warmly welcome you to buy or wholesale bulk Medical Accessory Device for sale here and get quotation from our factory.
Medical Accessory Device,Medical Device Accessory,Rigid Containers For Sterilization,Surgical Instrument Containers
Tonglu WANHE Medical Instrument Co., Ltd , https://www.tlvanhurhealth.com